1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-0937
  5. Product Images: Duloxetine

Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 12 images provide visual information about the product associated with Duloxetine NDC 70518-0937 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Duloxetine 60mg 70518 0937 04

Duloxetine 60mg 70518 0937 04

Duloxetine is a delayed-release medication available in capsule form with a strength of 60 mg. The medication comes in a bottle of 30 capsules and is only available with a prescription. The NDC number is 70518-0937-04 and the manufacturer is Rising Pharma, Inc. The medication should be kept out of the reach of children and stored at a temperature between 20-25°C (88-77°F), with a permitted excursion range of 15-30°C (59-86°F) as per the USP guidelines. The repackaging has been done by RemedyRepack Inc. in Indiana, PA. For direction regarding usage, please refer to the package insert.*

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

Duloxetine Delayed-Release 60mg Capsule is a prescription drug. The pack contains 30 capsules. It should be stored at a temperature range of 20-25°C (88-77°F) with excursions permitted to 15-30°C (59-86°F) and protected from children. To get dosage instructions, you can refer to the package insert, and it has been repackaged by RemedyRepack Inc., Indiana, PA 15701. The details like the NDC number, lot number, expiration date, and source NDC are available.*

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

Figure 1: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Relapse (MDD Study 5) - duloxetine fig1

Figure-2 - duloxetine fig2

Figure-2 - duloxetine fig2

Figure 3: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-1 - duloxetine fig3

Figure 3: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-1 - duloxetine fig3

Figure 4: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2 - duloxetine fig4

Figure 4: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-2 - duloxetine fig4

This appears to be a graph/chart showing the percentage of patients who improved while taking Duloxetine 60 mg BID, Duloxetine 60 mg QD, and a placebo. The x-axis measures the percentage of improvement in pain from baseline, ranging from 0% to 100%, while the y-axis shows the percentage of patients who experienced that level of improvement. There are also numbered tick marks on the x-axis at 10% intervals.*

Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1 - duloxetine fig5

Figure 7: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-1 - duloxetine fig5

Figure 8: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3 - duloxetine fig6

Figure 8: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3 - duloxetine fig6

This text appears to be a graph or chart showing the improvement of pain in patients with different doses of Duloxetine compared to a placebo. The X-axis shows the percent improvement in pain from baseline, and the Y-axis shows the percentage of patients who experienced that level of improvement. The doses of Duloxetine shown are 20 mg, 60 mg, and 120 mg once daily.*

Figure 9: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1 - duloxetine fig7

Figure 9: Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1 - duloxetine fig7

The plot shows the percentage of patients who experienced an improvement in pain from baseline, while taking either placebo or duloxetine at 60 or 120 mg once daily. The range of improvement varied from 0 to 100 percent. The abbreviation "BOCF" likely refers to a method of analyzing data, but the details are not provided in this text.*

duloxetine fig8

duloxetine fig8

This appears to be a graph showing the percentage of patients who improved with a placebo and Duloxetine, a drug prescribed at a dose of 60 mg once daily. There is also a line graph that shows the percentage improvement in pain from baseline. However, without additional context, it is difficult to provide a more specific description or interpretation of the data.*

duloxetine fig9

duloxetine fig9

This text appears to be a graph or chart displaying the percentage of pain improvement for a medical treatment using Placeto and Dulowetine at 60/120 mg once daily. It shows the percentage of patients that experienced improvement in pain over time, with baseline pain levels represented on the x-axis and percent improvement on the y-axis. Without further context, it is not possible to provide additional information.*

Structure - duloxetine str

Structure - duloxetine str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.